{
  "id": 15595094,
  "title": "Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site",
  "url": "https://urgent.news/2026/10/19/marvel-biosciences-advances-mb-204-toward-first-in-human-testing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-19T10:46:17.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/marvel-biosciences-advances-mb-204-toward-first-in-human-testing-selects-cmax-as-phase-i-clinical-trial-site"
  },
  "original_language": "en",
  "account": null,
  "summary": "CALGARY, Alberta , Oct. 19, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce that it has selected CMAX as the […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}